View in EDS HTML Full Text PDF Full Text

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.

Saved in:
Bibliographic Details
Title: Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Authors: Weisel, Katja1 (AUTHOR), Dimopoulos, Meletios A.2 (AUTHOR), Beksac, Meral3 (AUTHOR), Leleu, Xavier4 (AUTHOR), Richter, Joshua5 (AUTHOR), Heeg, Bart6 (AUTHOR), Patel, Sachin7 (AUTHOR), Majer, Istvan8 (AUTHOR), McFadden, Ian9 (AUTHOR), Mikhael, Joseph10 (AUTHOR) jmikhael@myeloma.org
Source: Leukemia & Lymphoma. Apr2024, Vol. 65 Issue 4, p481-492. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:10428194
DOI:10.1080/10428194.2023.2300051